Type 2 Diabetes Research Study
Researchers at UT Health San Antonio are conducting a study on how SGLT2 inhibitors affect the liver’s production of sugar and ketones in people with Type 2 Diabetes.
Fast Facts
Type 2 Diabetes or Elevated Blood Glucose Levels
Managing with Diet and/or Anti-Diabetic Medication
Compensation
Provided
Conducted in
San Antonio, TX
Study Background
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
SGLT2 inhibitors (like Empagliflozin) are medicines used to help lower blood sugar in people with type 2 diabetes. They work by helping your kidneys remove extra sugar through your urine.
These medications may also affect how your liver makes sugar and how your body produces ketones (a type of energy source). In addition to managing blood sugar, SGLT2 inhibitors have been shown to support heart and kidney health—even in people without diabetes. The goal of this research study is to examine how SGLT2 inhibitors affect the liver’s production of sugar and ketones.
If you have been diagnosed with type 2 diabetes or have elevated blood glucose levels, and you are managing your condition with diet or with anti-diabetic pills, you may be eligible to participate in this compensated study. Help advance diabetes research and apply today.
Study Background
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
SGLT2 inhibitors (like Empagliflozin) are medicines used to help lower blood sugar in people with type 2 diabetes. They work by helping your kidneys remove extra sugar through your urine.
These medications may also affect how your liver makes sugar and how your body produces ketones (a type of energy source). In addition to managing blood sugar, SGLT2 inhibitors have been shown to support heart and kidney health—even in people without diabetes. The goal of this research study is to examine how SGLT2 inhibitors affect the liver’s production of sugar and ketones.
If you have been diagnosed with type 2 diabetes or have elevated blood glucose levels, and you are managing your condition with diet or with anti-diabetic pills, you may be eligible to participate in this compensated study. Help advance diabetes research and apply today.
Additional Information
This study is conducted to understand how SGLT2 inhibitors (such as Empagliflozin) affect the liver’s production of sugar and ketones. By understanding these pathways, we can help prevent conditions like ketoacidosis, which happens when too many ketones build up in the blood and can become life-threatening. Additionally, this knowledge will enable us to improve treatment strategies for patients with type 2 diabetes.
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 30-75
- Diagnosed with type 2 diabetes or have elevated blood glucose levels
- Using diet and/or anti-diabetic pills to manage diabetes
- BMI between 21–45
Exclusion Criteria:
- Using injectables (e.g., insulin, Semaglutide, Tirzepatide) to treat diabetes
- Using DPP-4 inhibitors (e.g., sitagliptin) to treat diabetes
- Using TZDs (e.g., Actos) to treat diabetes
- Serious eye or kidney issues as a result of diabetes
- Regular heavy exercise
If you join this study, you will need to come to the clinic about 2 to 10 times over a period of up to three months. This includes your first screening visit and 2 to 9 additional visits on different days during the study. After your screening visit, you will return for several study visits. Four of these visits will be longer (about 8–9 hours), and during those visits, you will receive substance infusions.
Participants will be compensated for full study participation.
There is no cost for you to participate in our research study.